November 24, 2016 - By Darrin Black · 0 Comments
The stock of Ariad Pharmaceuticals Incorporated (NASDAQ:ARIA) registered an increase of 13.96% in short interest. ARIA’s total short interest was 36.60M shares in November as published by FINRA. Its up 13.96% from 32.12 million shares, reported previously. With 9.72M shares average volume, it will take short sellers 4 days to cover their ARIA’s short positions. The short interest to Ariad Pharmaceuticals Incorporated’s float is 21.17%. The stock increased 3.30% or $0.44 on November 23, hitting $13.79. About 3.64M shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 87.36% since April 22, 2016 and is uptrending. It has outperformed by 81.95% the S&P500.
ARIAD Pharmaceuticals, Inc. is an oncology company. The company has a market cap of $2.63 billion. The Firm is focused on transforming the lives of cancer patients with medicines. It currently has negative earnings. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.16, from 1.4 in 2016Q1. The ratio dropped, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Price Michael F accumulated 1.06% or 1.08 million shares. Palo Alto Investors Ltd Liability Com holds 1.42% or 2.54 million shares in its portfolio. Bnp Paribas Arbitrage Sa holds 0% or 6,954 shares in its portfolio. Moreover, Rhenman And Prtnrs Asset Mngmt has 0.82% invested in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 625,000 shares. Old Mutual Glob (Uk) Limited has invested 0.21% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Dekabank Deutsche Girozentrale has 0.01% invested in the company for 96,200 shares. Hudson Valley Investment Advsrs Adv owns 20,000 shares or 0.05% of their US portfolio. Consonance Lp owns 8.85M shares or 9.25% of their US portfolio. Pointstate Limited Partnership holds 3.80 million shares or 0.58% of its portfolio. Northern Trust Corp has 0.01% invested in the company for 2.22M shares. Nationwide Fund last reported 156,798 shares in the company. Peapack Gladstone reported 19,515 shares or 0% of all its holdings. Ameriprise Financial, a Minnesota-based fund reported 222,952 shares. Kcg Holding holds 150,016 shares or 0.02% of its portfolio. Legal & General Gru Public Limited Company holds 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 48,134 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 10 sales for $3.87 million net activity. $148,230 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares were sold by CLACKSON TIMOTHY P. 108,569 shares with value of $896,135 were sold by Radaelli Massimo on Friday, June 10. On Monday, June 13 LAVIDAS ATHANESE sold $626,039 worth of the stock or 76,250 shares.
Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. JMP Securities maintained it with “Market Outperform” rating and $9 target price in Wednesday, March 9 report. The firm earned “Outperform” rating on Monday, September 26 by Leerink Swann. The rating was downgraded by JMP Securities to “Mkt Perform” on Tuesday, October 25. The firm earned “Buy” rating on Wednesday, October 5 by Suntrust Robinson. On Monday, October 24 the stock rating was downgraded by JP Morgan to “Underweight”. The rating was maintained by JP Morgan with “Neutral” on Friday, August 7. The rating was initiated by Deutsche Bank with “Hold” on Thursday, November 3. The firm has “Underweight” rating by Barclays Capital given on Friday, July 29. The company was initiated on Tuesday, January 19 by Barclays Capital. As per Wednesday, May 11, the company rating was maintained by Barclays Capital.
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Another recent and important Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) news was published by Fool.com which published an article titled: “3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results” on November 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black